The reduction in quality of life experienced by PSS patients in our cohort is highlighted by comparison of the fatigue score, as measured by the FACIT-F, and the physical function component score of the SF-36 to that recently reported in a large cohort of Rheumatoid Arthritis patients with active disease who had failed anti-TNF therapy[21] The FACIT-F of 30.33 and the SF-36 role limitations, physical = 30.9 reported in the active RA group are strikingly similar to the scores of 30.1(FACIT-F) and 35.0 (SF-36 role limitations, physical) in our PSS cohort. The gene discussed is TNF; the disease is rheumatoid arthritis.